KIORA PHARMACEUTICALS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.4 USD | -0.90% |
|
-0.90% | -6.41% |
| Jul. 02 | Kiora Pharmaceuticals, Inc. Announces Board and Committee Changes | CI |
| Jun. 25 | Kiora Pharmaceuticals Appoints Roger A. Goldberg to its Scientific Advisory Board | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 40.56 | 27.17 | 19.11 | 6.162 | 4.017 | 13.19 | - | - |
| Enterprise Value (EV) 1 | 40.56 | 27.17 | 19.11 | 6.162 | 4.017 | 13.19 | 13.19 | 13.19 |
| P/E ratio | -4.49 x | -2.79 x | -0.85 x | -0.18 x | -0.19 x | 4.77 x | -1.64 x | -2.01 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 15.1 x | 2,264 x | - | - | - | 0.8 x | 6.59 x | 17.6 x |
| EV / Revenue | 15.1 x | 2,264 x | - | - | - | 0.8 x | 6.59 x | 17.6 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | -1,744,587 x | - | - | - | - | - |
| FCF Yield | - | - | -0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 11.2 | 15.3 | 35.1 | 200 | 854 | 2,971 | - | - |
| Reference price 2 | 3,607 | 1,775 | 543.6 | 30.87 | 4.702 | 4.440 | 4.440 | 4.440 |
| Announcement Date | 3/4/20 | 3/25/21 | 4/15/22 | 3/23/23 | 3/25/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.686 | 0.012 | - | - | - | 16.5 | 2 | 0.75 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -7.109 | -8.213 | -16.94 | -12.31 | -12.59 | 3.761 | -14.07 | -19.77 |
| Operating Margin | -264.67% | -68,439.67% | - | - | - | 22.79% | -703.58% | -2,636.2% |
| Earnings before Tax (EBT) 1 | -7.001 | -8.08 | -16.7 | -13.7 | -12.42 | 4.012 | -14.04 | -19.77 |
| Net income 1 | -7.097 | -8.092 | -16.39 | -13.58 | -13.04 | 4.012 | -14.04 | -19.77 |
| Net margin | -264.21% | -67,432.83% | - | - | - | 24.31% | -702.25% | -2,636.2% |
| EPS 2 | -802.8 | -637.2 | -637.2 | -167.0 | -24.21 | 0.9300 | -2.700 | -2.205 |
| Free Cash Flow | - | - | -10.95 | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/4/20 | 3/25/21 | 4/15/22 | 3/23/23 | 3/25/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | 16 | - | - | 0.5 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -8.649 | -3.569 | -2.402 | -3.703 | -2.635 | -1.917 | -2.633 | -5.919 | -2.119 | 13.22 | -3.144 | -3.198 | -3.119 | -3.931 | -4.073 |
| Operating Margin | - | - | - | - | - | - | - | - | - | 82.64% | - | - | -623.87% | - | - |
| Earnings before Tax (EBT) 1 | -8.683 | -3.565 | -2.401 | -5.119 | -2.611 | -1.869 | -2.614 | -5.763 | -2.178 | 13.45 | -3.137 | -3.191 | -3.113 | -3.911 | -4.053 |
| Net income 1 | -8.378 | -3.565 | -2.401 | -5.119 | -2.498 | -1.869 | -2.614 | -6.294 | -2.269 | 13.45 | -3.137 | -3.191 | -3.113 | -3.911 | -4.053 |
| Net margin | - | - | - | - | - | - | - | - | - | 84.08% | - | - | -622.53% | - | - |
| EPS 2 | -280.8 | -97.20 | -64.80 | -54.27 | -15.81 | -9.000 | -7.110 | -8.010 | - | 3.420 | -0.8100 | -0.7800 | -0.7500 | -0.7650 | -0.6300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/15/22 | 7/8/22 | 8/12/22 | 11/9/22 | 3/23/23 | 5/9/23 | 8/8/23 | 11/9/23 | 3/25/24 | 5/10/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | -11 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | 0.06 | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 3/4/20 | 3/25/21 | 4/15/22 | 3/23/23 | 3/25/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.44
USD
Average target price
33
USD
Spread / Average Target
+643.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.41% | 13.19M | |
| +19.40% | 124B | |
| +20.13% | 114B | |
| +21.11% | 25.83B | |
| -23.76% | 19.42B | |
| -18.17% | 16.2B | |
| -19.66% | 15.31B | |
| +54.68% | 14.32B | |
| +8.08% | 14.31B | |
| -48.79% | 14.19B |
- Stock Market
- Equities
- EYEG Stock
- Financials Kiora Pharmaceuticals, Inc.
